Lipfendra (Enlicitide): Uses, Dosage, Side Effects & Cost

Lipfendra (enlicitide) is a once-daily pill that the FDA approved on July 16, 2026, to lower LDL (“bad”) cholesterol in adults with high cholesterol, including a genetic form called heterozygous familial hypercholesterolemia (HeFH). It works by blocking a protein called PCSK9, and it’s the first oral drug in its class — every other PCSK9 inhibitor on the market is an injection.

Why it matters:

• No needles. It replaces injectable PCSK9 inhibitors with a tablet you swallow once a day.
• Strong LDL reduction. Clinical trials showed placebo-adjusted LDL-C drops of 56–59%.
• Works alongside statins. It’s designed as an add-on for people who still have high LDL despite taking a statin.
• Strict timing matters. It has to be taken on an empty stomach with only water, black coffee, or plain tea — food cuts absorption almost in half.

Keep reading for dosage instructions, the full side effect profile, drug interactions, trial data, storage rules, and how Lipfendra stacks up against Repatha, Praluent, and Leqvio.

Also read: Tylenol with Naproxen: Uses, Side Effects & How It Works

Lipfendra at a Glance

What Is Lipfendra (Enlicitide)?

Lipfendra is the brand name for enlicitide (given as enlicitide decanoate), a drug Merck developed under the research code MK-0616. It’s a macrocyclic peptide — a large, ring-shaped molecule — engineered to attach to PCSK9 and stop it from working. Merck markets it as LIPFENDRA® in 20 mg tablets, sold in 30-count bottles with a built-in desiccant.

Peptide drugs like this one don’t normally survive the stomach or absorb well when swallowed, which is why PCSK9 inhibitors have always been injections. Merck solved that problem by adding sodium caprate, a permeation enhancer, to the tablet. Even with that boost, only about 1% of an oral dose actually reaches the bloodstream — but because enlicitide is so potent at blocking PCSK9, that small fraction is enough to do the job.

Until this approval, patients who needed a PCSK9 inhibitor had to use injectable drugs like Repatha or Praluent. Lipfendra changes that by putting PCSK9 inhibition into pill form for the first time.

What Is Lipfendra Used For?

The FDA approved Lipfendra as an adjunct to diet and exercise to lower LDL cholesterol in adults with:

• Hypercholesterolemia (high LDL cholesterol), including patients already on a statin who need further LDL lowering
• Heterozygous familial hypercholesterolemia (HeFH), an inherited condition that causes very high LDL from a young age

It is not a first-line treatment, and there are no listed contraindications in its label. Doctors typically prescribe it for patients whose LDL remains too high despite moderate- or high-intensity statin therapy, with or without other cholesterol drugs. It has not been studied in children, and its safety and effectiveness in pediatric patients haven’t been established.

How Does Lipfendra Work?

Lipfendra targets PCSK9, a protein your liver makes that normally attaches to LDL receptors on liver cells and marks them for breakdown. Fewer LDL receptors means your liver can pull less LDL cholesterol out of your bloodstream, so LDL levels rise.

Enlicitide binds to PCSK9 and blocks it from attaching to LDL receptors. With PCSK9 out of the way, your liver keeps more LDL receptors on its surface, clears more LDL from your blood, and your LDL-C level drops. In trials, a single dose of 10 mg or more cut circulating free PCSK9 by more than 90% within half an hour to an hour, and the 20 mg approved dose produces close to the maximum possible LDL-lowering effect the drug can achieve. Doctors can typically detect a measurable drop in LDL-C as early as 4 weeks after starting treatment.

This is the same basic mechanism used by injectable PCSK9 inhibitors — Lipfendra just delivers it through a peptide engineered to survive digestion well enough to work as a pill. Testing at four times the maximum dose also found no clinically significant effect on heart rhythm (QTc interval).

Lipfendra Dosage and How to Take It

Lipfendra’s timing rules are stricter than most cholesterol medications, and getting them right meaningfully affects how well the drug works.

• Standard dose: One 20 mg tablet, taken by mouth once daily
• Take it in the morning, on an empty stomach, with only water, black coffee, or plain tea
• Swallow the tablet whole. Don’t split, crush, or chew it
• Wait at least 30 minutes after your dose before eating anything or drinking anything besides water, black coffee, or plain tea
• You can take Lipfendra alongside your other regular medications — no separate spacing is required for those

Why the timing matters: in pharmacokinetic studies, taking Lipfendra 30 minutes after a meal — rather than before one — cut the drug’s absorption (AUC) by 48% and its peak level (Cmax) by 50%, and delayed how quickly it reached peak concentration. Taking it with black coffee or plain tea instead of water didn’t meaningfully change absorption, so those two beverages are fine substitutes if you don’t like drinking plain water first thing in the morning.

If You Miss a Dose

• Take the missed dose as soon as you remember, as long as it’s at least 30 minutes before your next food or drink (other than water, black coffee, or plain tea)
• Never take 2 doses in the same day to make up for a missed one

If You Take Too Much

There’s no specific antidote or treatment for a Lipfendra overdose. If you or someone else takes too much, call your healthcare provider, contact Poison Control at 1-800-222-1222 (or visit poisonhelp.org), or go to the nearest emergency room right away.

What Lipfendra Looks Like and How to Store It

Each Lipfendra tablet is a white-to-off-white, oval, film-coated pill with grey specks, debossed with “119” on one side and Merck’s corporate logo on the other. It’s dispensed in 30-tablet bottles (NDC 0006-5084-01) with a child-resistant cap and a built-in desiccant packet.

• Store at room temperature, 68°F to 77°F (20°C to 25°C); brief excursions to 59–86°F (15–30°C) are fine, such as during travel
• Keep it in its original bottle, tightly closed, to protect it from moisture
• Don’t remove the desiccant packet from the bottle
• Keep out of reach of children

Active ingredient: enlicitide decanoate. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium caprate; the film coating contains calcium carbonate, an ethylene glycol/vinyl alcohol graft copolymer, glyceryl mono- and dicaprylocaprate, polyvinyl alcohol, talc, and carnauba wax as a polishing agent.

Clinical Trial Results

The FDA approval rests on two Phase 3 trials from Merck’s CORALreef program, comparing Lipfendra to placebo over 52 weeks, with the main efficacy readout measured at week 24.

Both reductions were statistically significant (p<0.001). Patients were randomized 2:1 to Lipfendra or placebo in both trials, and everyone stayed on their background statin therapy throughout — patients already using an injectable PCSK9 inhibitor were excluded from enrolling.

One data-handling detail worth understanding: in CORALreef Lipids, a post-hoc analysis that excluded a small number of “biologically impossible” (i.e., negative or zero) baseline LDL-C values found a slightly larger reduction of 60% instead of 56%. That’s a secondary analysis, not the trial’s primary result, so it’s worth knowing when comparing headline numbers you might see reported elsewhere.

“In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C.” — Dr. Ann Marie Navar, cardiologist at UT Southwestern Medical Center and lead investigator on the CORALreef Lipids trial, via Merck

“We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.” — Katherine Wilemon, CEO of the Family Heart Foundation, via Merck

It’s worth noting: LDL-lowering is a surrogate marker. A separate, larger trial — CORALreef Outcomes (NCT06008756), enrolling more than 14,500 participants — is still underway to confirm whether Lipfendra actually reduces heart attacks and strokes, not just cholesterol numbers. Merck is also running CORALreef Extension (long-term safety), CORALreef Pediatric, and CORALreef Combination trials as part of the broader, 19,000-plus-participant CORALreef program.

Lipfendra Side Effects

In the CORALreef Lipids trial, side effects with Lipfendra were similar to placebo overall, and similar numbers of patients in both groups stopped treatment because of a side effect. In the CORALreef HeFH trial, two side effects showed up more often with Lipfendra than placebo:

Serious Side Effects: Allergic Reactions

As with any medication, a serious allergic reaction is possible, even though it wasn’t a standout signal in trials. Stop taking Lipfendra and get medical help right away if you notice:

• Swelling of the face, lips, mouth, tongue, or throat, or trouble swallowing
• Breathing problems, wheezing, or a racing heart
• Hives, itching, or skin rash
• Fever, general ill feeling, or swollen lymph nodes
• Severe dizziness, fainting, nausea, vomiting, or stomach cramps

Key safety points:

• No new or unexpected safety signals emerged compared to earlier trials, and there are no listed contraindications on the FDA label.
• This list covers only the most common and most serious reactions from the pivotal trials and label. For the complete list, see the official Prescribing Information and Patient Information/Medication Guide.
• Report side effects to the FDA at 1-800-FDA-1088 (or fda.gov/medwatch); in Canada, report to Health Canada at 866-234-2345.

Drug, Food, and Beverage Interactions

Lipfendra has a notably clean interaction profile for a once-daily oral drug. Based on lab (in vitro) studies, it has very low potential to interact with other drugs through cytochrome P450 enzymes or common drug transporters.

In dedicated interaction studies, Lipfendra didn’t meaningfully change blood levels of lithium, levothyroxine, digoxin, warfarin, atorvastatin, alendronate, lisinopril, or oral semaglutide tablets — and none of those drugs (nor atorvastatin) changed enlicitide’s own levels either. That’s why the label says Lipfendra can be taken alongside other medications without special spacing.

• Food: Taking Lipfendra after eating cuts absorption by roughly half — always take it on an empty stomach.
• Beverages: Water, black coffee, and plain tea don’t meaningfully affect absorption. Other drinks haven’t been studied for timing purposes.
• Alcohol: It isn’t known whether alcohol affects Lipfendra. Talk to your doctor if you drink regularly.

Always tell your healthcare provider about every prescription drug, over-the-counter medicine, vitamin, and supplement you take — this isn’t necessarily a complete list of every possible interaction.

Who Should Not Take Lipfendra / Special Populations

Lipfendra’s label lists no formal contraindications, but your doctor will still want your full medical history before prescribing it. Talk to your doctor if you:

• Are pregnant or planning pregnancy. Because lowering LDL-C also lowers other cholesterol-derived substances the fetus may need, Lipfendra may cause fetal harm, and doctors are advised to discontinue it once pregnancy is recognized unless the benefits outweigh the risks. Data in pregnant patients is limited.
• Are breastfeeding or plan to. It isn’t known whether enlicitide passes into human breast milk. You and your doctor should weigh the benefits of breastfeeding against your need for the medication.
• Have kidney problems. Even severe renal impairment and hemodialysis only modestly raised drug exposure in studies, and the label doesn’t consider these increases clinically meaningful — but your doctor may still want to monitor you.
• Have liver problems. Moderate hepatic impairment didn’t change how the drug is processed; severe hepatic impairment hasn’t been studied.
• Are 65 or older. In trials, 45% of patients were 65+ and 12% were 75+, with no differences in safety or effectiveness compared to younger adults.
• Are under 18. Safety and effectiveness haven’t been established in children; a dedicated pediatric trial (CORALreef Pediatric) is ongoing.
• Are taking other cholesterol medications, since your regimen may need to change, or have had an allergic reaction to enlicitide or any of its ingredients.

This is general information, not a complete list of precautions. Your doctor needs your full medical history to determine if Lipfendra is right for you.

Lipfendra vs. Repatha vs. Praluent vs. Leqvio

The biggest practical difference is the needle-free, once-daily format, paired with the strict empty-stomach timing that the injectable options don’t require. Effectiveness looks broadly comparable on paper, but head-to-head trial data between Lipfendra and these other options isn’t yet available, so cross-drug comparisons should be read as directional, not definitive.

How Much Does Lipfendra Cost?

Merck has said it plans to price Lipfendra at roughly $10.50 per day for a one-month supply (about $315/month, or about $10 per 30-tablet bottle co-pay range varies). As with most brand-name drugs, your actual out-of-pocket cost will depend on your insurance coverage and any manufacturer assistance programs, such as the Merck Access Program or MerckHelps for eligible patients.

FAQs

Disclaimer: The information in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider before starting any new medication or health routine.